| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD009144 |
| P8608 | Fatcat ID | release_qa5ygvpljvbvfjvucbxoqle3zy |
| P50 | author | Christian Gluud | Q26265142 |
| Goran Bjelakovic | Q28320793 | ||
| P2093 | author name string | Miodrag N Krstic | |
| Jelena S Rudic | |||
| Vanja Giljaca | |||
| P2860 | cites work | Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis | Q24289436 |
| What is meant by intention to treat analysis? Survey of published randomised controlled trials | Q24647858 | ||
| Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study | Q24653790 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Guidelines on the management of osteoporosis associated with chronic liver disease | Q24685899 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease | Q69734919 | ||
| Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis | Q72357203 | ||
| Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo | Q72434479 | ||
| Renal failure associated with intravenous diphosphonates | Q72546632 | ||
| Management of osteoporosis in primary biliary cirrhosis | Q74280837 | ||
| Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group | Q74817608 | ||
| Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia | Q79903139 | ||
| Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis | Q81513622 | ||
| American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis | Q84476629 | ||
| How should meta-regression analyses be undertaken and interpreted? | Q28193388 | ||
| Bisphosphonates: from bench to bedside | Q28251212 | ||
| Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses | Q29619185 | ||
| Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? | Q29619328 | ||
| Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches | Q33201947 | ||
| Estimating required information size by quantifying diversity in random-effects model meta-analyses. | Q33521365 | ||
| Bisphosphonates for steroid induced osteoporosis | Q33908281 | ||
| Hepatic osteodystrophy. | Q34109988 | ||
| Intravenous zoledronic acid in postmenopausal women with low bone mineral density | Q34116443 | ||
| Osteoporosis prevention, diagnosis, and therapy | Q34140339 | ||
| Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report | Q34307115 | ||
| Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? | Q34955886 | ||
| The use of bisphosphonates in the treatment of osteoporosis | Q36089455 | ||
| Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper | Q36355771 | ||
| Bias in clinical intervention research. | Q36380552 | ||
| Treatment of bone disorders in liver disease | Q36537610 | ||
| Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease | Q36716615 | ||
| Safety considerations with bisphosphonates for the treatment of osteoporosis. | Q36920653 | ||
| Bone densitometry and vertebral fracture assessment | Q37765867 | ||
| Bone Disorders in Chronic Liver Diseases | Q37811999 | ||
| Mortality after all major types of osteoporotic fracture in men and women: an observational study. | Q39490012 | ||
| Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management | Q40589823 | ||
| Hip fractures in the elderly: a world-wide projection | Q41104614 | ||
| Adverse effects of bisphosphonates. A comparative review | Q41230892 | ||
| The crippling consequences of fractures and their impact on quality of life | Q41597014 | ||
| Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial | Q42878211 | ||
| Primary biliary cirrhosis: epidemiology helping the clinician | Q43109086 | ||
| Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. | Q43466373 | ||
| Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs | Q43917199 | ||
| Renal Failure with the Use of Zoledronic Acid | Q44628533 | ||
| Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation | Q46277951 | ||
| Bone disease in primary biliary cirrhosis: independent indicators and rate of progression | Q50684179 | ||
| Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease | Q51802919 | ||
| A comparison of methods to detect publication bias in meta-analysis | Q52067551 | ||
| Methods for combining randomized clinical trials: strengths and limitations | Q52599212 | ||
| Antifracture efficacy of antiresorptive agents are related to changes in bone density | Q52918360 | ||
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
| Ueber die Einwirkung des Chloracetyls auf phosphorige Säure | Q56851818 | ||
| Osteoporosis | Q57417202 | ||
| Fracture Risk in People With Primary Biliary Cirrhosis: A Population-Based Cohort Study | Q58376321 | ||
| Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls | Q58376324 | ||
| P921 | main subject | osteoporosis | Q165328 |
| primary biliary cholangitis | Q1072420 | ||
| P577 | publication date | 2011-05-11 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Bisphosphonates for osteoporosis in primary biliary cirrhosis |
Search more.